Does LipoDyne Have Side Effects?

For most adults who already drink coffee, nothing much. One hundred milligrams is roughly one cup, taken at the same time of day most people take their first one, and the body handles it the same way.

The people who notice something usually notice one of three things, and all three belong to the caffeine rather than to the botanicals: a faster or more noticeable heartbeat in the first hour, a restlessness that is hard to separate from ordinary morning alertness, and a poorer night if the capsule went in late.

The botanical rows are far less likely to announce themselves at these amounts. Cayenne extract can be felt by some people as warmth or mild stomach irritation, and that is the most common non-caffeine complaint in the category.

The honest summary is that this is a lightly dosed capsule for a lightly stimulated effect, and its side-effect profile is a proportionate one. That is not a claim of safety for everybody, which is what the rest of this page is for.

This is the most consequential row on the panel and also the best characterised, which is a fortunate combination.

Two ingredients on this panel have appeared in case reports and in the Drug-Induced Liver Injury Network record. Both signals sit above the amounts printed here, and both are worth knowing in specific terms rather than as a general warning.

Concentrated green tea extract. The DILIN study identified a genetic association with green tea liver injury, and a case series described injuries linked to a commercial weight-loss product containing it. The US Pharmacopeia review and the LiverTox chapter are the two best summaries. The amounts involved run well above the 250 mg of extract on this label, and a systematic review of green tea safety puts the risk in proportion.

Garcinia cambogia. The DILIN analysis of garcinia and green tea covers the reported cases, and the individual reports are stark: an acute liver failure report, a transplant case series and a 2019 hepatotoxicity case report. The LiverTox chapter is the reference summary, and a 2023 trial in women with fatty liver sits on the other side of the question.

Two things follow. Anybody with existing liver disease has a reason to ask before starting a product containing either ingredient. And anybody who develops persistent abdominal pain, unusual fatigue, dark urine or yellowing should stop the capsule and be seen, which is the general rule for the whole category rather than a statement about this bottle. A 2017 review of supplement-related liver injury sets out how uncommon and how serious those events are.

Black pepper extract at 10 mg is the smallest row on the panel and the one with the clearest interaction.

Piperine inactivates CYP3A, an enzyme responsible for clearing a large share of prescription medicines, which the inactivation study measured directly. Slowing that enzyme raises the blood level of a medicine that depends on it, which is the same mechanism that makes piperine useful as an absorption aid.

Statins, several calcium channel blockers, some immunosuppressants, several psychiatric medicines and a number of antivirals are cleared that way. A review of piperine’s physiological effects covers the breadth of it.

Ten milligrams is a small amount and the sensible response is proportionate: name the product at the next appointment that was happening anyway, by its six ingredients, and let the person with the prescribing record decide whether it matters. That is one sentence, said once, and it is the whole of the action this page recommends.

Reported effects in the category with the row each most plausibly belongs to. This is not a list of effects measured in trials of this product, because no trial of this product exists.

The table is arranged by row rather than by severity on purpose, because the useful question when something is noticed is which ingredient to suspect. On a panel with six printed amounts that question has an answer; on a proprietary blend it does not.

Taking the capsule with a small meal rather than on an empty stomach resolves most of the digestive entries at no cost to anything else.

• Persistent abdominal pain, unusual tiredness, dark urine or yellowing of the skin or eyes. Stop and be seen. These are the liver symptoms described in the case literature above, they are uncommon, and they are the reason that section is specific.
• A racing or irregular heartbeat that does not settle. Stop, and count the caffeine in the rest of the day before assuming the capsule acted alone.
• Sleep that does not recover after moving the capsule earlier. Stop. A supplement that costs sleep is a net loss whatever else it does.
• Anxiety, agitation or panic symptoms. Stop. The panic-disorder literature is clear enough that this does not need a trial period.
• Anything that starts within days of the first capsule and stops within days of the last. That pattern is what makes an effect attributable, and it is worth acting on rather than waiting out.

The commercial side of stopping is straightforward. The 30-day return window on the listing runs from delivery and covers a change of mind, so a bottle stopped in week two is a bottle that can still go back. The refund page has the procedure.

There is no tapering requirement and no reason to finish a bottle that is not suiting you. One capsule a day builds nothing that needs unwinding beyond the ordinary caffeine habit.

Every piece of evidence on this page describes a single ingredient. Nobody has given these six materials together, in these proportions, to anybody in a published study.

That matters more for safety than it does for effect, because interactions between botanicals are the part of this category least characterised. A review of multi-ingredient caffeine supplements is candid about how thin that literature is, and the NEJM study of emergency-department visits is the best available measure of how often supplements in general send somebody to hospital, which is rarely and disproportionately from weight products and stimulants.

The second gap is that a retail bottle carries no assay. A DILIN assay of supplement contents found discrepancies between labels and contents often enough to make the point, and no seller in this category ships a certificate with a bottle.

Neither gap is a reason to expect a problem from a modestly dosed capsule. Both are reasons to describe the safety of this product as proportionate and uncharacterised rather than as established, and NCCIH’s guidance on using supplements wisely is the plainest general reading on that distinction.